Lung Cancer RTK
Lung cancer is the leading cause of cancer-related mortality worldwide. It is generally divided into two broad histological classifications: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC comprises about 80-85% of all lung cancers. Receptor tyrosine kinases (RTKs) are essential components to cellular signaling pathways and are often overexpressed or otherwise dysregulated by genetic mutations, fusion, or gene amplification. RTKs are generally activated by receptor specific ligands, leading to autophosphorylation and the subsequent recruitment of downstream signaling proteins. The most common RTK amplification in NSCLC is that for epidermal growth factor receptor (EGFR). Also, two of the most common mutations in EGFR include an exon 19 deletion, E746-A750, and a point mutation L858R. In addition to EGFR, several other RTKs may become aberrantly activated in NSCLC, including ALK, ROS1, HER2/ErbB2, Met, Ret, FGF Receptor 1, and NTRK.
Product List
| Target | Catalog# | Product Name | Reactivity | Application |
|---|---|---|---|---|
EGFR | EGFR Rabbit Monoclonal antibody | Human,Mouse,Rat | WB,IHC,IF,IP,ELISA |
Related Products
Super-sensitive ECL chemiluminescent reagent
References
- Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Rebuzzi SE, et al. Int J Mol Sci. 2021. [PMID: 33807876]
- Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Riely GJ, et al. Clin Cancer Res. 2006. [PMID: 17189394]
- Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Kosaka T, et al. Cancer Res. 2004. [PMID: 15604253]
- Mechanisms of receptor tyrosine kinase activation in cancer. Du Z, Lovly CM. Mol Cancer. 2018. [PMID: 29455648]
- Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. Reinmuth N, et al. Int J Cancer. 2006. [PMID: 16557579]
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Sung H, et al. CA Cancer J Clin. 2021. [PMID: 33538338]
- Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Carrot-Zhang J, et al. Cell Rep. 2021. [PMID: 33535033]
